STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer

被引：0
|
作者：
Abdi Ghaffari
Nichole Peterson
Kasra Khalaj
Natasha Vitkin
Andrew Robinson
Julie-Ann Francis
Madhuri Koti
机构：
[1] Queen’s University,Department of Biomedical and Molecular Sciences
[2] Queen’s University,Department of Obstetrics and Gynecology, Kingston Health Sciences Center
[3] Queen’s University,Department of Oncology, Kingston Health Sciences Center
[4] Queen’s University,Cancer Biology and Genetics, Queen’s Cancer Research Institute
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：440 / 449
页数：9
相关论文
共 50 条
  • [1] STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
    Ghaffari, Abdi
    Peterson, Nichole
    Khalaj, Kasra
    Vitkin, Natasha
    Robinson, Andrew
    Francis, Julie-Ann
    Koti, Madhuri
    BRITISH JOURNAL OF CANCER, 2018, 119 (04) : 440 - 449
  • [2] STING agonist treatment increases response to chemotherapy and immune checkpoint blockade therapy in a syngeneic murine model of high-grade serous ovarian cancer
    Ghaffari, Abdi
    Peterson, Nichole
    Khalaj, Kasra
    Robinson, Andrew
    Francis, Julie-Ann
    Koti, Madhuri
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [3] Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
    Wan, Changxin
    Keany, Matthew P.
    Dong, Han
    Al-Alem, Linah F.
    Pandya, Unnati M.
    Lazo, Suzan
    Boehnke, Karsten
    Lynch, Katherine N.
    Xu, Rui
    Zarrella, Dominique T.
    Gu, Shengqing
    Cejas, Paloma
    Lim, Klothilda
    Long, Henry W.
    Elias, Kevin M.
    Horowitz, Neil S.
    Feltmate, Colleen M.
    Muto, Michael G.
    Worley, Michael J.
    Berkowitz, Ross S.
    Matulonis, Ursula A.
    Nucci, Marisa R.
    Crum, Christopher P.
    Rueda, Bo R.
    Brown, Myles
    Liu, Xiaole Shirley
    Hill, Sarah J.
    CANCER RESEARCH, 2021, 81 (01) : 158 - 173
  • [4] CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
    Yang, Moran
    Lu, Jiaqi
    Zhang, Guodong
    Wang, Yiying
    He, Mengdi
    Xu, Qing
    Xu, Congjian
    Liu, Haiou
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
  • [5] PD-1 IMMUNE CHECKPOINT BLOCKADE ENHANCES ERADICATION OF DISSEMINATED OVARIAN CANCER
    Serda, Rita
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A438 - A438
  • [6] Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer
    Hosseinzadeh, Shahnaz
    Imani, Mahsa
    Pourfarzi, Farhad
    Jafari, Narjes
    Abediankenari, Saeid
    Safarzadeh, Elham
    MEDICAL ONCOLOGY, 2024, 41 (05)
  • [7] Improving chemotherapy response of immunologically cold high-grade serous ovarian cancer with loss of PTEN using STING agonist.
    Shakfa, Noor
    Lightbody, Elizabeth
    Afriyie-Asante, Afrakoma
    Kannen, Vinicius
    Koti, Madhuri
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 120 - 120
  • [8] Enhancement of immune checkpoint PD-1 blockade efficacy in ovarian cancer
    Drakes, Maureen
    Mehrotra, Swati
    Potkul, Ronald
    Liu, Yueying
    Stack, M. Sharon
    Stiff, Patrick
    CANCER RESEARCH, 2018, 78 (13)
  • [9] C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer
    Zhang, Chen
    Cao, Kankan
    Yang, Moran
    Wang, Yiying
    He, Mengdi
    Lu, Jiaqi
    Huang, Yan
    Zhang, Guodong
    Liu, Haiou
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [10] The tumor immune microenvironment modulates response to chemotherapy in high-grade serous epithelial ovarian cancer
    Koti, Madhuri
    Edwards, Andrew
    Squire, Jeremy A.
    CANCER RESEARCH, 2014, 74 (19)
12345